Tag Archive: Psilocybin

Hardcore trip enthusiasts have been using psilocybin mushrooms for years in an attempt to gain access to the Technicolor trapdoor into the unknown. Of course, there are also those who just want to watch their friends’ faces melt off and listen for subliminal messages on all their favorite records.

The scientific community, however, says there is more to the “magic mushroom” than just an emotional glimpse inside the looking glass of the universe, but similar to our friend marijuana, it also has medicinal properties that could one day be used to cure a myriad of mental afflictions.

Researchers from the University of Florida recently published a study in the journal Experimental Brain Research that suggests specific components of psilocybin mushrooms have the ability to create new brain cells. The discovery can be used to develop ground breaking new treatments for severe mental conditions…even improve learning.

In fact, researchers suggest that when given to mice, psilocybin mushrooms proved successful in restoring crippled brain cells as well as easing the symptoms of conditions like Post Traumatic Stress Disorder and depression — sometimes even working as a cure.

Continue reading

The mushrooms, my friend, are blowing in the wind...

Plants use a variety of methods to spread their seeds, including gravity, forceful ejection, and wind, water, and animal dispersion. But what of the mushrooms, whose spores also need to be strewn far and wide to ensure their propagation?

Biologists have long thought that the spores produced by a mushroom’s cap simply drop into the wind and blow away. The problem with that notion, said Emilie Dressaire, a professor of experimental fluid mechanics at Trinity College in Hartford, Conn., is that spores can be dispersed even when the air is still. So how do the mushrooms do it? Dressaire, along with Marcus Roper of the University of California, Los Angeles (UCLA), believe they have found the answer: they make their own wind.

Past studies from Imperial College London strongly suggest that psilocybin in “shrooms” can cure depression and PTSD, and now studies from South Florida confirm that “shrooms” and psilocybin are like the miracle plant cannabis that is gradually being legalized, a miracle product of the earth with multiple potent medical uses.

Psilocybin Mushrooms

New studies show that psilocybin removes the trauma and fear from memories in the minds of mice, and even stimulates the growth of a significant amount of new brain cells.

Studies from The University of South Florida indicate that psilocin (or psilocybin, which metabolizes into psilocin), found in “shrooms”, triggers new brain cell growth, and erases frightening memories from mice. Mice trained to fear electric shock when hearing a noise associated with the shock, stopped reacting in fear to the noise when given a small dose of psilocybin, much more quickly, in contrast to mice given no psilocybin. “They simply lost their fear”, exclaimed the co-author of the study, Dr. Juan Sanchez-Ramos, a professor of movement disorders.

Much more research could be done by ordinary people and professors alike, if the US government and other too powerful governments weren’t at war with their own citizens over drugs. Psilocybin mushrooms, or “shrooms” of course, are illegal in the United States, and illegal in other countries simply because the US and western powers bullied them into compliance or persuaded them by some means we don’t know of. Psilocybin mushrooms are a genus of mushroom, called “psilocybe”. Such mushrooms that fall into this genus are Psilocybe Cubensis, or Psilocybe Bispora.

People are eager to look into the idea of using Psilocybin Mushrooms to cure PTSD (Post Traumatic Stress Disorder), chronic depression, and a wide range of other mental and physical ailments, so we will just have to get government off our backs to do so. These mushrooms are harmless, cannot cause overdose, cannot cause death (unless you become frightened and hurt yourself on accident, but that is extremely rare and potentially unheard of, and is the case for almost any psychoactive substance).

Continue reading

PHOTO: Magic mushrooms

Researchers have discovered that low doses of psilocybin, the psychedelic compound in magic mushrooms, speed the extinction of the conditioned fear response in mice. The results could pave the way for psilocybin to be explored as a potential treatment for post-traumatic stress disorder and other related conditions in humans.

Reporting in the journal Experimental Brain Research, a team led by Dr. Briony Catlow of the Lieber Institute for Brain Development sought to determine how psilocybin affected the learning and removal of a conditioned fear response.

Mice were injected with varying doses (0.1, 0.5, 1.0 and 1.5 mg/kg) of psilocybin, 1.0 mg/kg of ketanserin (a drug that acts oppositely on the receptor which binds psilocybin), or a saline control. Twenty-four hours later, the animals were placed in a testing chamber and conditioned to fear a 15-second audio cue. The mice heard the cue, and after 30 seconds, received very brief electric shocks delivered through the chamber floor. Each mouse underwent ten trials, each separated by 210 seconds. After ten trials, all of the animal subjects froze in fear after the start of the 15-second audio.

The next day, the mice were placed in the chamber again and underwent the same process. Except this time, the shock was left out. The goal here was to effectively retrain the mice to not fear the audio cue and disassociate it with the shock. The researchers found that after only three trials, mice treated with low doses of psilocybin (0.1 and 0.5 mg/kg) no longer froze after hearing the audio cue. But mice injected with higher doses of psilocybin or ketanserin didn’t stop freezing until the tenth trial. Mice that were injected with a saline control still froze in fear after ten trials.

Continue reading

Drugs derived from magic mushrooms could help treat people with severe depression. Scientists believe the chemical psilocybin, the psychedelic ingredient in magic mushrooms, can turn down parts of the brain that are overactive in severely depressive patients. The drug appears to stop patients dwelling on themselves and their own perceived inadequacies.

However, a bid by British scientists to carry out trials of psilocybin on patients in order to assess its full medical potential has been blocked by red tape relating to Britain’s strict drugs laws. Professor David Nutt, professor of neuropsychopharmacology at Imperial College London, will tell a conference today that because magic mushrooms are rated as a class-A drug, their active chemical ingredient cannot be manufactured unless a special licence is granted.

“We haven’t started the study because finding companies that could manufacture the drug and who are prepared to go through the regulatory hoops to get the licence is proving very difficult,” said Nutt. “The whole field is so bedevilled by primitive old-fashioned attitudes. Even if you have a good idea, you may never get it into the clinic, it seems.”

Research by Nutt has found that psilocybin switches off part of the brain called the anterior cingulate cortex. It was known that this area is overactive in individuals suffering from depression. In his tests on healthy individuals, it was found that psilocybin had a profound effect on making these volunteers feel happier weeks after they had taken the drug, said Nutt – who was sacked as the chairman of the Advisory Council on the Misuse of Drugs in 2009 after repeatedly clashing with government ministers about the dangers and classification of illicit drugs.

Continue reading

Mind-altering compounds, such as LSD and psilocybin, stirred controversy in the 1960s. As the counter-culture’s psychedelic drugs of choice, the widespread use – and abuse – of hallucinogens prompted tougher anti-drug laws. That also led to a crackdown on clinical studies of the drugs’ complex psychological effects.

However, now the U.S. Food and Drug Administration (FDA) has begun to approve limited research into the potential benefits of psychedelic drugs.

No one is more aware of the stigma attached to psychedelics than Rick Doblin, director of the Multi-Disciplinary Association for Psychedelic Studies (MAPS), a drug development firm that funds FDA-approved clinical trials to examine the potential therapeutic uses of psychedelics.

Doblin says the virtual blackout on research that resulted from aggressive federal drug-control policies in the 1960s finally began to ease in 1990, when new regulators at the FDA decided to take a fresh look at psychedelic drugs.

UCLA researchers found the psychedelic compound, psilocybin – found naturally in certain mushrooms – can ease end-of-life anxiety in cancer patients.

“They decided they would put science over politics and permit research to go forward,” he says. “They were willing to acknowledge that these drugs could be administered in a safe-enough context and that there were promising hints of potential benefits and therapeutic uses. Today, there is more psychedelics research taking place than in the last 40 years.”

One especially active focus of FDA-approved research has involved MDMA – also known as “Ecstasy.”

This potent drug is being studied for its potential therapeutic value for sex-abuse victims and combat veterans suffering from chronic, treatment-resistant post-traumatic stress disorder, or PTSD.

Continue reading

Magic mushrooms’ active ingredient psilocybin enables users to experience more vivid recollections.

A drug derived from magic mushrooms could help people withdepression by enabling them to relive positive and happy moments of their lives, according to scientists including the former government drug adviser, Professor David Nutt.

Two studies, for which scientists struggled to find funding because of public suspicion and political sensitivity around psychedelic drugs, have shed light on how magic mushrooms affect the brain.

Nutt, from Imperial College London, was sacked as a government drug adviser after claiming tobacco and alcohol were more dangerous than cannabis and psychedelic drugs such as ecstasy and LSD.

He believes prejudice and fear have prevented important scientific work on psychedelic drugs. Research began in the 1950s and 60s but was stopped by the criminalisation of drugs and stringent regulations which made the work costly.

“Everybody who has taken psychedelics makes the point that these can produce the most profound changes in the state of awareness and being that any of them have experienced,” said Nutt.

The drugs had been used for millennia, he said, since psychedelic mushrooms grew in the Elysian fields of Greece. Aldous Huxley wrote The Doors Of Perception about the insight such drugs gave him into the life of the mind.

Continue reading

The active ingredient in psychedelic mushrooms decreases brain activity, possibly explaining the vivid, mind-bending effects of the drug, a new study finds.

Amanita Muscaria 19

The decreases were focused in regions that serve as crossroads for information in the brain, meaning that information may flow more freely in a brain on mushrooms. The findings could be useful in developing hallucinogenic treatments for some mental disorders.

“There is increasing evidence that the regions affected are responsible for giving us our sense of self,” study author Robin Carhart-Harris, a postdoctoral researcher at Imperial College London, wrote in an email to LiveScience.

“In other words, the regions affected make up what some people call our ‘ego.’ That activity decreases in the ‘ego-network’ supports what people often say about psychedelics, that they temporarily ‘dissolve the ego.'”

Continue reading

Cancer survivor Lauri Reamer lived in constant dread that her disease would return, until she took a psychedelic drug in a Johns Hopkins University study.

The 48-year mother of three was given psilocybin, the main ingredient in the “magic mushrooms” of the 1960s, as a remedy to ease anxiety. She spent most of her first “trip” crying, then emerged from the next with less anxiety, better sleep and happier relations with family and friends, she recalled.

The experience “really cracked me open,” said Reamer, an anesthesiologist at Johns Hopkins in Baltimore before she was diagnosed with leukemia. “It let me be in life again, instead of this place of fear where I had been living.”

Almost 40 years after Richard Nixon called former Harvard University psychologist Timothy Leary the most dangerous man in America for promoting use of hallucinogenic substances, there is a rebirth of interest in their therapeutic benefits. Reamer was enrolled in a clinical trial at Johns Hopkins to relieve fear of death in cancer patients, one of a half-dozen similar studies under way at New York University, Harvard, the University of California, Los Angeles, and the University of New Mexico.

The new research, largely driven by the psychiatric community, is also testing psychedelics for use against depression, chronic headaches and addiction as current scientists, much like their 1960s predecessors, seek to understand the “consciousness-expanding” effects of the drugs.

Continue reading

ECSTASY pills would be given to Australian bushfire victims, flood survivors and soldiers suffering post-traumatic stress disorder, in a controversial proposal for a clinical trial.

Small overseas studies have shown the illegal party drug to be effective for traumatised patients who have not responded to other treatments. An Australian psychologist is now calling for similar research to be funded here.

Psychologist Stephen Bright, who is affiliated with a group of international clinicians pushing for the medical use of psychotropic drugs such as ecstasy, marijuana and magic mushrooms, said trials in the US and Switzerland showed ecstasy, or MDMA, was safe and effective.

”Patients were followed up for up to an average of 41 months after the last treatment sessions and the findings showed that the therapeutic benefits have been sustained over time,” said Mr Bright, an addiction specialist at Curtin University.

”We’ve had bushfires in Victoria, there’s been flooding in Queensland, we have troops in Afghanistan, there is quite a high incidence of post-traumatic stress disorder. But half of people do not respond to [conventional] treatments. If we had this alternative then that would provide people with significant hope and the opportunity to recover.”

Continue reading

Psilocybin can improve mental health

altAccording to new research by the Johns Hopkins School of Medicine in Baltimore, magic mushrooms can have long-lasting positive effects on people’s well-being. After their use of the drug, volunteers reported positive effects such as an increased sense of inner peace and increased ability to empathize with others.

It has been known for quite some time that the active constituent of magic mushrooms, psilocybin, can induce profound experiences. However, when the ‘trip’ becomes too strong, the experience often includes strong negative emotions such as anxiety and despair. The researchers, led by professor of behavioural biology Roland Griffiths, defined an optimal dose, inducing influential and mystical experiences without any negative side-effects.

Continue reading


Get every new post delivered to your Inbox.

Join 266 other followers

%d bloggers like this: